Acrivon Therapeutics, Inc.
Acrivon Therapeutics is a U.S. biotechnology company developing targeted small-molecule medicines using its predictive precision proteomics approach. Its AP3 platform combines cellular signaling measurements with drug discovery and clinical biomarker strategies. The company has focused primarily on oncology and has expanded its work into immunology and inflammatory diseases. Based in Watertown, Massachusetts, Acrivon is listed on Nasdaq under ACRV. The company's approach seeks to connect drug mechanisms with patient selection and clinical development decisions.
Company at a glance
Corporate information
- Company entity
- Acrivon Therapeutics, Inc.
- Headquarters / principal office
- United States
- Founded
- Not verified
- Ownership / capital status
- Publicly tradedPublicly listed
- Official corporate reference
- https://acrivon.com/
- LinkedIn company page
- Independent company page not verified
Profile review: 2026-11-08 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Listed issuer and R&D focus
Nasdaq: ACRV
predictive phosphoproteomics · precision small molecules
oncology · immunology · inflammatory disease
Last independently verified:
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
Acrivon Therapeutics is a U.S. biotechnology company developing targeted small-molecule medicines using its predictive precision proteomics approach. Its AP3 platform combines cellular signaling measurements with drug discovery and clinical biomarker strategies. The company has focused primarily on oncology and has expanded its work into immunology and inflammatory diseases. Based in Watertown, Massachusetts, Acrivon is listed on Nasdaq under ACRV. The company's approach seeks to connect drug mechanisms with patient selection and clinical development decisions.
Business, technology & evidence
- SecuritiesNasdaq: ACRV
Individual program detail is not recorded. Consult the original sources below.
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Showing 0 / 0 related items
No cataloged update explicitly mentions this company.
Same-field reading (not company-specific)
Research this company together
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinSources & open questions
- Official issuer and R&D disclosure · Acrivon Therapeutics, Inc. ↗Acrivon Therapeutics, Inc. ·
Inclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.